Pharmacogenomics Used in the Intensive Care Unit
This special issue belongs to
|Research & Reviews : Journal of Medical Science and Technology
Deadline for Manuscript Submission
|March 31st, 2023
Deadline for Publication
|April 15, 2023
Special Issue Description
Pharmacogenomics is progressively getting to be a profitable instrument for progressing well-being results, decreasing wellbeing care costs, and dodging antagonistic medicate responses. Whereas the application of pharmacogenomics is very common in oncology and cardiology, schedule utilization of this innovation is uncommon in certain other areas counting Injury and Basic Care Surgery. Within the intensive care unit (ICU) setting, where profoundly variable and deficiently medicated efficacies, as well as the visit and unusual adverse drug reactions (ADRs), happen, pharmacogenomics (PGx) offers an opportunity to progress well-being results.
The challenge of pharmacotherapy within the ICU is that patients may concurrently get the restorative treatment of numerous sedative-analgesics, antimicrobials, antifungal drugs, anticoagulants, and in some cases paralytics as well as solutions to restrain gastric corrosive emission. Basic ailment combined with preexisting constant infections regularly comes about in hepatic or renal inadequacy and, as a result, modifications in understanding the body's deposition and reaction to drugs. Hence, the choice of the right pharmaceutical at the correct measurements is challenging, but basic, to maintain a strategic distance from serious and startling toxicities and to guarantee restorative adequacy.
*Pharmacogenomics *Adverse drug reactions (ADRs) *Intensive care unit (ICU) *Sedative-analgesics *Antimicrobials *Antifungal drugs *Anticoagulants
Manuscript Submission information
Manuscripts should be submitted online by registering and logging in to this link. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed.
Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent on email address:[email protected] for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page.